Human malignant brain tumor response to herpes simplex thymidine kinase (HSVtk)/ganciclovir gene therapy

M Izquierdo; V Martín; P de Felipe; J M Izquierdo; A Pérez-Higueras; M L Cortés; J F Paz; A Isla; M G Blázquez

Human malignant brain tumor response to herpes simplex thymidine kinase (HSVtk)/ganciclovir gene therapy

Gene Ther. 1996 Jun;3(6):491-5.

Authors

M Izquierdo¹, V Martín, P de Felipe, J M Izquierdo, A Pérez-Higueras, M L Cortés, J F Paz, A Isla, M G Blázquez

Affiliation

¹ Departamento de Biología Molecular/Centro de Biología Molecular Severo Ochoa, Facultad de Ciencias (módulo-C-X), Universidad Autónoma de Madrid, Spain.

PMID: 8789798

Abstract

Growing cells from human brain tumors have been treated in vitro and in vivo with murine therapeutic retroviral producer cells. The therapeutic retrovirus carried the potential suicide gene thymidine kinase (tk) from the herpes simplex virus (HSV). After a few days, in which a large proportion of the tumoral cells had the opportunity to acquire a copy of the retrovirus, treatment with ganciclovir was initiated and considered responsible for considerable cell death both in vitro and in vivo. The in vivo experiments were performed in five adult patients who had failed standard therapy and were expected to survive only a few weeks.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

3T3 Cells
Adult
Animals
Antiviral Agents / therapeutic use*
Brain Neoplasms / mortality
Brain Neoplasms / pathology
Brain Neoplasms / therapy*
Cell Death / drug effects
Coculture Techniques
Fibroblasts
Ganciclovir / therapeutic use*
Genetic Therapy / methods*
Glioblastoma / mortality
Glioblastoma / pathology
Glioblastoma / therapy*
Humans
Magnetic Resonance Imaging
Mice
Neoplasm Recurrence, Local
Polymerase Chain Reaction
Rats
Simplexvirus / enzymology
Simplexvirus / genetics*
Survival Analysis
Thymidine Kinase / biosynthesis*
Thymidine Kinase / genetics
Transfection / methods
Tumor Cells, Cultured

Substances

Antiviral Agents
Thymidine Kinase
Ganciclovir